Literature DB >> 16531764

Hypermethylation of the MLH1 promoter with concomitant absence of transcript and protein occurs in small patches of crypt cells in unaffected mucosa from sporadic colorectal carcinoma.

Gerard J Nuovo1, Hidewaki Nakagawa, Kaisa Sotamaa, Albert de la Chapelle.   

Abstract

Hypermethylation of the MLH1 promoter is present in most sporadic colorectal cancers and leads to the abrogation of MLH1 transcription. The significance of the hypermethylation of the promoter that can be detected in rare foci of cells in the normal colonic epithelium adjacent to the carcinoma is unclear. The purpose of this study was to determine the distribution of hypermethylation of the MLH1 promoter DNA with MLH1 RNA expression by RT in situ PCR and MLH1 protein expression by immunohistochemistry in normal colonic tissues. Hypermethylation of the MLH1 promoter DNA was not evident in sections of normal colon from 10 people with no history of colon cancer. MLH1 RNA and protein were detected diffusely throughout the colonic epithelium in these 10 controls. In comparison, hypermethylation of either of 2 regions of the promoter was evident in the normal mucosa from cases adjacent to adenocarcinoma of the colon. In situ analysis of the DNA methylation showed that there were rare foci that involved small groups of cells, typically toward the middle and surface area of a given crypt. In these areas, small foci of colonic epithelial cells, typically in groups of 5 to 10, were found to lack MLH1 RNA and protein in adjacent serial sections, consistent with silencing of the gene by hypermethylation that may play a role in the origin of these neoplasms. It is concluded that the rare foci of hypermethylation of the MLH1 promoter in normal colon epithelium from people with colorectal cancer is associated with silencing of the gene that may play a role in the early evolution of these neoplasms. A combination of methylation-specific in situ PCR with in situ RNA and protein analysis can assist in documenting rare foci of promoter hypermethylation-induced gene silencing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16531764     DOI: 10.1097/00019606-200603000-00003

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  8 in total

Review 1.  Colorectal cancer: a model for epigenetic tumorigenesis.

Authors:  J J L Wong; N J Hawkins; R L Ward
Journal:  Gut       Date:  2006-07-13       Impact factor: 23.059

2.  DNA methylotype analysis in colorectal cancer.

Authors:  Jinsheng Yu; Robert R Freimuth; Robert Culverhouse; Sharon Marsh; Mark A Watson; Howard L McLeod
Journal:  Oncol Rep       Date:  2008-10       Impact factor: 3.906

3.  Reduced mRNA expression in paraffin-embedded tissue identifies MLH1- and MSH2-deficient colorectal tumours and potential mutation carriers.

Authors:  Annegret Müller; Dirk Zielinski; Nicolaus Friedrichs; Barbara Oberschmid; Sabine Merkelbach-Bruse; Hans K Schackert; Markus Linnebacher; Magnus von Knebel Doeberitz; Reinhard Büttner; Josef Rüschoff
Journal:  Virchows Arch       Date:  2008-06-26       Impact factor: 4.064

4.  p16INK4a gene promoter hypermethylation in mucosa as a prognostic factor for patients with colorectal cancer.

Authors:  Yvonne Wettergren; Elisabeth Odin; Staffan Nilsson; Göran Carlsson; Bengt Gustavsson
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

5.  Endoglin promoter hypermethylation identifies a field defect in human primary esophageal cancer.

Authors:  Zhe Jin; Zhenfu Zhao; Yulan Cheng; Ming Dong; Xiaojing Zhang; Liang Wang; Xinmin Fan; Xianling Feng; Yuriko Mori; Stephen J Meltzer
Journal:  Cancer       Date:  2013-07-24       Impact factor: 6.860

6.  Epigenetic downregulation of the DNA repair gene MED1/MBD4 in colorectal and ovarian cancer.

Authors:  J Harrison Howard; Andrey Frolov; Ching-Wei D Tzeng; Ashley Stewart; Andrew Midzak; Amar Majmundar; Andrew Godwin; Martin Heslin; Alfonso Bellacosa; J Pablo Arnoletti
Journal:  Cancer Biol Ther       Date:  2009-01-20       Impact factor: 4.742

7.  Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers.

Authors:  Terje Ahlquist; Guro E Lind; Vera L Costa; Gunn I Meling; Morten Vatn; Geir S Hoff; Torleiv O Rognum; Rolf I Skotheim; Espen Thiis-Evensen; Ragnhild A Lothe
Journal:  Mol Cancer       Date:  2008-12-31       Impact factor: 27.401

8.  Profiling CpG island field methylation in both morphologically normal and neoplastic human colonic mucosa.

Authors:  N J Belshaw; G O Elliott; R J Foxall; J R Dainty; N Pal; A Coupe; D Garg; D M Bradburn; J C Mathers; I T Johnson
Journal:  Br J Cancer       Date:  2008-06-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.